Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
2019-nCoV Vaccine mRNA-1273
/ immunology
Adolescent
Adult
Aged
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
COVID-19
/ prevention & control
Clinical Trials, Phase III as Topic
Female
Humans
Immunogenicity, Vaccine
Male
Middle Aged
Randomized Controlled Trials as Topic
SARS-CoV-2
/ immunology
Sensitivity and Specificity
Spike Glycoprotein, Coronavirus
/ immunology
Vaccine Efficacy
Young Adult
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
07 Jan 2022
07 Jan 2022
Historique:
pubmed:
24
11
2021
medline:
15
1
2022
entrez:
23
11
2021
Statut:
ppublish
Résumé
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later, with values reported in standardized World Health Organization international units. All markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Vaccine recipients with postvaccination 50% neutralization titers 10, 100, and 1000 had estimated vaccine efficacies of 78% (95% confidence interval, 54 to 89%), 91% (87 to 94%), and 96% (94 to 98%), respectively. These results help define immune marker correlates of protection and may guide approval decisions for messenger RNA (mRNA) COVID-19 vaccines and other COVID-19 vaccines.
Identifiants
pubmed: 34812653
doi: 10.1126/science.abm3425
pii: 10.1126/science.abm3425
pmc: PMC9017870
mid: NIHMS1800809
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-50Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI069476
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148575
Pays : United States
Organisme : NIH HHS
ID : S10 OD028685
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069412
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068614
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI054165
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068635
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U01 AI068635
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Vaccine. 2007 May 10;25(19):3816-26
pubmed: 17368878
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Cell. 2021 Jun 24;184(13):3467-3473.e11
pubmed: 34133941
Epidemiology. 2016 May;27(3):368-77
pubmed: 26841057
Stat Med. 1998 Apr 30;17(8):857-72
pubmed: 9595616
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Lancet. 2021 Oct 9;398(10308):1377-1380
pubmed: 34534516
Clin Infect Dis. 2019 May 2;68(10):1713-1717
pubmed: 30202873
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
JAMA. 2021 Jul 6;326(1):46-55
pubmed: 34081073
J Clin Invest. 2019 Nov 1;129(11):4838-4849
pubmed: 31589165
Nat Med. 2021 Sep;27(9):1493-1494
pubmed: 34518674
Clin Infect Dis. 2012 Jun;54(11):1615-7
pubmed: 22437237
Clin Infect Dis. 2022 Aug 24;75(1):e878-e879
pubmed: 35100611
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
N Engl J Med. 2021 May 13;384(19):1866-1868
pubmed: 33761203
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Int J Biostat. 2016 May 1;12(1):3-19
pubmed: 27227715
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Stat Med. 2012 Nov 10;31(25):2973-84
pubmed: 22711298
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
PLoS Comput Biol. 2019 Apr 1;15(4):e1006952
pubmed: 30933973
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
PLoS One. 2021 Oct 19;16(10):e0258858
pubmed: 34665829